The Problem at the Heart of Public Access
The intended beneficiary of public access is “the American public,” and we need so much more than access to the biomedical literature.
The FDA Spies On Its Own Scientists — Cloaks and Daggers Emerge When Scientists and Authorities Clash
A lurid story of intramural hijinks at the FDA shows how far from mission an organization can drift when it gets its priorities wrong.
ClinicalTrials.gov — Too Many Studies Are Registered Late, Published Late, and Smaller Than Planned
Registering clinical trials after enrollment has commenced may lead to the perception that medical researchers are peeking.